Journal Information
Share
Download PDF
More article options
Original article
Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study
Tislelizumab, un nuevo anticuerpo monoclonal anti-PD-1 para el cáncer urotelial: estudio de vida real
Z. Wang, H. Bi, Y.D. Wang, Q. Liu, B. Shao, C.Q. Li, C. Fu, S. Fu, G.Y. Shan, A. Chen, C.C. Lv, Y. Zeng
Corresponding author
Servicio de Urología, Hospital Oncológico de la Universidad Medica de China, Liaoning Cancer Hospital & Institute, Shenyang, China